Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
The trial found that after 5 years, Wegovy significantly reduced the risk of death from heart disease by 15% and reduced the risk of cardiovascular events including nonfatal heart attacks and strokes by 20%, compared to an inactive placebo
Both medications work through the same GLP-1 pathway
Income disparities are similar, with 44.6% of adults in households earning under $15,000 diagnosed as obese
In the SURMOUNT 1 trial, tirzepatide at doses of 5 mg, 10 mg and 15 mg were evaluated against placebo, with pooled tirzepatide groups resulting in significant decreases in total cholesterol, LDL-C, VLDL-C, FFA, and triglycerides and an increase in HDL-C at week 72 of follow-up [35]
US$ 25.14
US$ 28.79
US$ 20.57
US$ 29.27
US$ 25.38
